Participation of an endogenous Ca++-blinding protein activator in the development of drug-induced supersensitivity of striatal dopamine receptors.
D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001058:Apomorphine / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D002352:Carrier Proteins / Q000378:metabolism / Q000502:physiology*; D003024:Clozapine / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D003986:Dibenzocycloheptenes / Q000494:pharmacology*; D004298:Dopamine / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D008297:Male; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects*; D013239:Stereotyped Behavior / Q000187:drug effects
D014150:Antipsychotic Agents; D002352:Carrier Proteins; D003986:Dibenzocycloheptenes; D011954:Receptors, Dopamine; D000262:Adenylyl Cyclases; D003024:Clozapine; D006220:Haloperidol; D001058:Apomorphine; D002118:Calcium; D004298:Dopamine